Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05436912 · ClinicalTrials.gov registry record · Phase 1
A Study of Effects of Selpercatinib in Hepatically Impaired Participants and Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT05436912 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 36 participants.
The verdict
NCT05436912, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
The main purpose of this study is to assess how selpercatinib gets into the blood stream and how long it takes the body to remove it when administered to participants with impaired hepatic function compared to healthy participants. Information about safety and tolerability will be collected. The study will last up to about 7 weeks, inclusive of screening period.
Interventions
- DRUG Selpercatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2018-12-10 |
| Est. Completion | 2019-10-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05436912
The ClinicalTrials.gov registry entry for NCT05436912 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Selpercatinib is the first listed.
NCT05436912 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05436912 about?
NCT05436912 is a clinical study titled "A Study of Effects of Selpercatinib in Hepatically Impaired Participants and Healthy Participants". The main purpose of this study is to assess how selpercatinib gets into the blood stream and how long it takes the body to remove it when administered to participants with impaired hepatic function compared to healthy participants. Information about safety and tolerability will be collected. The stu...
What is the current status of trial NCT05436912?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2018-12-10. Estimated completion is 2019-10-30.
What interventions are being tested in trial NCT05436912?
The interventions under investigation include: Selpercatinib (DRUG).
Who is sponsoring clinical trial NCT05436912?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.